I have received an advertisement: “Stem Cell Technologies: World Market Outlook 2012-2022”
It is well understood that stem cell bubble is basically over – a lot of resources was burned, no any reasonable results were obtained. However a lot of promises continue to be issued:
With our study you also assess the R&D pipeline, seeing trends and outlooks. You find discussions of treatments in development, by therapeutic area and organisation:
• Autoimmune diseases - modifying the immune system
• Diabetes - restoring pancreatic function
• Oncology and cancer treatment
• Cardiovascular diseases - healing the heart and vascular system
• Neurological and cerebrovascular disorders - regenerating CNS tissue
• Ophthalmic disorders - potential for overcoming sight loss
• Bioartificial livers and hepatic regeneration with stem and progenitor cells
• Dermatology - developments in cellular skin repair
• Adipose-derived stem cells for autologous treatments
• Regenerative dentistry - potential for biotechnological tooth replacement.
You find prospects for embryonic, adult and induced pluripotent stem cells from 2012.
Market value for 2014 and prospects for the future
What will happen next? The biotechnology industry will develop many products using stem cells and increase revenues there from 2012 to 2022. The R&D pipeline is extensive. Overall world revenue will reach $7.3bn in 2014, our report forecasts.
Well, from the list I was impressed by the application for regenerative dentistry – why not? If the task is to present stem cells as a panacea so I would suggest starting with sexual dysfunction! And very, let's say, “modest” revenue of $7.3bn confirms that the situation with stem cell business is not very promising.
No comments:
Post a Comment